Propella Therapeutics, Inc. announced its presentation of updated Phase 1/2a data of PRL-02 (abiraterone decanoate) for the treatment of advanced prostate cancer at the 2023 ASCO Genitourinary (GU) Cancers Symposium on February 16, 2023. PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA. Also, recently issued U.S. patent 11,559,534 expands the PRL-02 IP estate with additional composition of matter and methods of use claims.